Related Experiment Video
Updated: Jul 4, 2026

LipidUNet-Machine Learning-Based Method of Characterization and Quantification of Lipid Deposits Using iPSC-Derived Retinal Pigment Epithelium
Published on: July 28, 2023
Unfolding the Therapeutic Potential of Chemical Chaperones for Age-related Macular Degeneration
Theodor Sauer1, Mrinali Patel, Chi-Chao Chan
1Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Abstract:
Recent studies suggest that pathological processes involved in age-related macular degeneration (AMD) might induce endoplasmic reticulum (ER) stress. Growing evidence demonstrates the ability of chemical chaperones to decrease ER stress and ameliorate ER stress-related disease phenotypes, suggesting that the field of chaperone therapy might hold novel treatments for AMD. In this review, we examine the evidence suggesting a role for ER stress in AMD. Furthermore, we discuss the use of chaperone therapy for the treatment of ER stress-associated diseases, including other neurodegenerative diseases and retinopathies. Finally, we examine strategies for identifying potential chaperone compounds and for experimentally demonstrating chaperone activity in in vitro and in vivo models of human disease.
Insights
Endoplasmic reticulum (ER) stress may play a role in age-related macular degeneration (AMD). Chemical chaperones show promise for treating ER stress-related diseases, including AMD, by reducing ER stress and disease symptoms.
Area of Science:
- Ophthalmology
- Neuroscience
- Cell Biology
Background:
- Emerging evidence links endoplasmic reticulum (ER) stress to pathological processes in age-related macular degeneration (AMD).
- ER stress is implicated in various neurodegenerative diseases and retinopathies.
- Chemical chaperones are known to reduce ER stress and associated disease phenotypes.
Purpose of the Study:
- To review the evidence for ER stress in AMD.
- To discuss the therapeutic potential of chaperone therapy for ER stress-associated diseases, including AMD.
- To explore strategies for identifying and validating chaperone compounds for disease treatment.
Main Methods:
- Literature review of studies on ER stress and AMD.
- Analysis of research on chaperone therapy in neurodegenerative diseases and retinopathies.
- Examination of methods for identifying and testing chaperone compounds in disease models.
Main Results:
- Significant evidence suggests ER stress is involved in the pathogenesis of AMD.
- Chaperone therapy is a potential therapeutic strategy for managing ER stress-related conditions.
- Various strategies exist for discovering and validating new chaperone compounds.
Conclusions:
- ER stress is a relevant factor in age-related macular degeneration.
- Chaperone therapy offers a promising avenue for novel AMD treatments.
- Further research into chaperone compounds and their mechanisms is warranted for treating ER stress-related diseases.
Related Concept Videos
Molecular Chaperones and Protein Folding
The...
Molecular Chaperones and Protein Folding
The...
iPS Cell Differentiation
